A real-world study to assess risk of major cardiovascular events across baricitinib or tofacitinib treated patients: Analysis of a national claim database

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 31 Oct 2022

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Baricitinib (Primary) ; Tofacitinib (Primary)
Indications Inflammatory bowel diseases; Psoriatic arthritis; Rheumatoid arthritis
Focus Adverse reactions

26 Oct 2022 Results published in the European Journal of Clinical Pharmacology
25 Jun 2021 New trial record
05 Jun 2021 Results presented at the 22nd Annual Congress of the European League Against Rheumatism.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com